AIM ImmunoTech Inc. (AIMI)
OTCMKTS
· Delayed Price · Currency is USD
0.1000
0.00 (0.00%)
May 9, 2025, 4:00 PM EDT
AIM ImmunoTech Employees
As of December 31, 2024, AIM ImmunoTech had 23 total employees, including 21 full-time and 2 part-time employees. The number of employees decreased by 5 or -17.86% compared to the previous year.
Employees
23
Change (1Y)
-5
Growth (1Y)
-17.86%
Revenue / Employee
$7,727
Profits / Employee
-$787,273
Market Cap
7.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
CytoDyn | 9 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
AIM ImmunoTech News
- 3 days ago - AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - GlobeNewsWire
- 4 weeks ago - AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewsWire
- 5 weeks ago - NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire
- 5 weeks ago - AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 2 months ago - AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - GlobeNewsWire